{"id":"https://openalex.org/W2374468475","doi":null,"title":"Development of a Pure Antiestrogen Fulvestrant","display_name":"Development of a Pure Antiestrogen Fulvestrant","publication_year":2002,"publication_date":"2002-01-01","ids":{"openalex":"https://openalex.org/W2374468475","mag":"2374468475"},"language":"en","primary_location":{"id":"mag:2374468475","doi":null,"is_oa":false,"landing_page_url":"https://en.cnki.com.cn/Article_en/CJFDTOTAL-GLYZ200202028.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764396500","display_name":"The Chinese Journal of Clinical Pharmacology","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4320800687","host_organization_name":"Chinese Pharmaceutical Association","host_organization_lineage":["https://openalex.org/P4320800687"],"host_organization_lineage_names":["Chinese Pharmaceutical Association"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"The Chinese Journal of Clinical Pharmacology","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002357459","display_name":"An Fu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"An Fu","raw_affiliation_strings":["-RongCUI LanZHU De-Qiu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"-RongCUI LanZHU De-Qiu","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5002357459"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.187251,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10756","display_name":"Estrogen and related hormone effects","score":0.9545999765396118,"subfield":{"id":"https://openalex.org/subfields/1310","display_name":"Endocrinology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10756","display_name":"Estrogen and related hormone effects","score":0.9545999765396118,"subfield":{"id":"https://openalex.org/subfields/1310","display_name":"Endocrinology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.027899999171495438,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.014399999752640724,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":1.0},{"id":"https://openalex.org/keywords/antiestrogens","display_name":"antiestrogens","score":0.8220000267028809},{"id":"https://openalex.org/keywords/tamoxifen","display_name":"tamoxifen","score":0.8579999804496765},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8080000281333923},{"id":"https://openalex.org/keywords/estrogen-receptor","display_name":"estrogen receptor","score":0.8889999985694885},{"id":"https://openalex.org/keywords/endometrial-cancer-risk","display_name":"endometrial cancer risk","score":0.6169999837875366},{"id":"https://openalex.org/keywords/endometrial-proliferation","display_name":"endometrial proliferation","score":0.6169999837875366},{"id":"https://openalex.org/keywords/mechanism-of-action","display_name":"mechanism of action","score":0.6710000038146973},{"id":"https://openalex.org/keywords/clinical-assessment","display_name":"clinical evaluation","score":0.40299999713897705}],"concepts":[{"id":"https://openalex.org/C2776067312","wikidata":"https://www.wikidata.org/wiki/Q50429983","display_name":"Antiestrogen","level":5,"score":0.9720069766044617},{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.9674785137176514},{"id":"https://openalex.org/C2777176818","wikidata":"https://www.wikidata.org/wiki/Q412178","display_name":"Tamoxifen","level":4,"score":0.8232951164245605},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6238055229187012},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.5384400486946106},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5372661352157593},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.49353039264678955},{"id":"https://openalex.org/C2777164284","wikidata":"https://www.wikidata.org/wiki/Q277954","display_name":"Estrogen","level":2,"score":0.4887795150279999},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.44677096605300903},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4261012077331543},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3928990364074707},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.29169028997421265},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2291049361228943},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.168271005153656}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2374468475","doi":null,"is_oa":false,"landing_page_url":"https://en.cnki.com.cn/Article_en/CJFDTOTAL-GLYZ200202028.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764396500","display_name":"The Chinese Journal of Clinical Pharmacology","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4320800687","host_organization_name":"Chinese Pharmaceutical Association","host_organization_lineage":["https://openalex.org/P4320800687"],"host_organization_lineage_names":["Chinese Pharmaceutical Association"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"The Chinese Journal of Clinical Pharmacology","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2406612827","https://openalex.org/W2166171580","https://openalex.org/W2030676208","https://openalex.org/W2001876005","https://openalex.org/W1980698036","https://openalex.org/W2172209768","https://openalex.org/W2064246732","https://openalex.org/W2488212174","https://openalex.org/W1983497273","https://openalex.org/W2003233390"],"abstract_inverted_index":{"Clinical":[0],"experience":[1],"with":[2,18,80],"the":[3,9,15,63,81,101,110],"nonsteroidal":[4],"antiestrogen":[5,12,53],"tamoxifen":[6,61],"hasestablished":[7],"unequivocally":[8],"value":[10],"of":[11,51,65,84,95,113],"therapy":[13],"in":[14,62],"treatment":[16,64],"ofpatients":[17],"breast":[19],"carcinoma.":[20,47],"But":[21],"tamoxifen-like":[22],"drugs":[23],"have":[24,35,58],"estrogen-like":[25],"actionson":[26],"certain":[27],"tissues":[28],"and":[29,119],"their":[30],"intrinsic":[31],"partial-agonist":[32],"effects":[33],"may":[34,57],"undesiredconsequences,":[36],"such":[37,73],"as":[38],"increased":[39,44],"endometrial":[40,46],"proliferation,":[41],"a":[42,74,77],"slightly":[43],"riskof":[45],"A":[48],"new":[49],"class":[50],"specific":[52],"without":[54],"any":[55],"agonisteffects":[56],"advantages":[59],"over":[60],"patients":[66],"withestrogen":[67],"dependent":[68],"disease.":[69],"The":[70],"search":[71],"for":[72,91,100],"drug":[75],"revealed":[76],"number":[78],"ofcompounds":[79],"appropriate":[82],"effect,":[83],"which":[85],"fulvestrant":[86],"(ICI":[87],"l82780,AstraZeneca)":[88],"was":[89],"selected":[90],"clinical":[92,117,120],"evaluation":[93],"because":[94],"its":[96],"greater":[97],"potencyand":[98],"affinity":[99],"estrogen":[102],"receptor":[103],"(ER).":[104],"In":[105],"this":[106],"paper,":[107],"we":[108],"reviewed":[109],"mode":[111],"ofaction":[112],"fulvestrant,":[114],"preclinical":[115],"data,":[116],"data":[118],"uses.":[121]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2016-06-24T00:00:00"}